Rifaximin Versus Lactulose in Renal Failure

• Status: Unknown status
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate patients with cirrhosis of the liver and renal failure and determine if the administration of rifaximin as compared to lactulose is associated with less frequent and/or slower progression to severe hepatic encephalopathy. If one is associated with lower blood ammonia levels. And, if one is associated with lower breath hydrogen and methane levels.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Weill Medical College of Cornell University
• Treatments: Lactulose; Rifamycins; Rifaximin

Criteria

Inclusion Criteria:

• cirrhosis of liver of any etiology

• progressive renal failure

• stage 0-2 hepatic encephalopathy

Exclusion Criteria:

• pregnant women